| NCT Number | NCT07455084 |
| Lead Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Conditions | Schizophrenia |
| Enrollment | 8 participants |
| Start Date | 2026-03-20 |
| Primary Completion | 2026-04-10 (estimated) |
| Study Completion | 2026-05-03 (estimated) |
| Updated on ClinicalTrials.gov | 2026-03-06 |